PRQR

ProQR Announces Publication in Nature Medicine for Sepofarsen in Leber Congenital Amaurosis 10

An End to This Rare Syndrome Could Be an Opportunity for Investors

ProQR Announces Closing of Underwritten Public Offering of Ordinary Shares with Full Exercise of Underwriters' Option to Purchase Additional Shares

ProQR Announces Virtual Presentation at American Association for Pediatric Ophthalmology and Strabismus (AAPOS) 2021

ProQR Prices $90 Million Underwritten Public Offering of Ordinary Shares

ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares

PRQR Stock: 7 Things to Know About High-Flying ProQR Therapeutics